Second look laparotomy and ovarian cancer

S. Kehoe
DOI: https://doi.org/10.1002/JSO.2930570314
1994-11-01
Journal of Surgical Oncology
Abstract:I read with interest the report by Zorlu et al. that effects on quality of life need addressing. The assessment appeared in the April 1994 issue of the Journal of Surgiof response to new therapeutic modalities remains one cal Oncology on the use of second look laparotomy (SLL) area where SLL could be justified, and hence SLL should in ovarian cancer management { 1). I agree with their be retained for research purposes. Otherwise, SLL cannot comments that SLL will detect disease when other methbe indicated. ods fail, but stating that SLL still plays a significant role in the management of ovarian cancer in patients with Stages 11, 111, and IV disease must be questioned. Exposing patients with malignancy to a second laparotomy should be carefully considered and the information accrued used to influence therapy and outcome. All patients in the study were exposed to six cycles of platin-based therapy, and presently no other effective treatment is available for those with residual disease (with the possible exception of Taxol). Although the authors state that individual cases may justify SLL, randomised trials have not proven a survival benefit with SLL (2 ,3 ) , and the I .
What problem does this paper attempt to address?